Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diabetes and nephropathy.

M Luiza Caramori1, Michael Mauer

  • 1Endocrine Division, Universidade Federal do Rio Grande do Sul, Brazil and bDepartment of Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455, USA.

Current Opinion in Nephrology and Hypertension
|April 17, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial.

Diabetes care·2026
Same author

Shared multicellular injury programs of acute and chronic kidney disease enable mechanistic patient stratification.

medRxiv : the preprint server for health sciences·2026
Same author

Cardio-Kidney-Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease.

Diabetes, obesity & metabolism·2026
Same author

Association Between Off-Label Use of Cardio-Kidney-Metabolic Therapies and Risk of Cardiovascular Events in Type 1 Diabetes: A Real-World Evidence Study.

Diabetes, obesity & metabolism·2026
Same author

Heterogeneity in the relationships between albuminuria and glomerular structure in type 1 and type 2 diabetes.

Kidney international·2025
Same author

Urinary Complement proteome strongly linked to diabetic kidney disease progression.

Nature communications·2025
Same journal

Primary prevention of chronic kidney disease in type 2 diabetes mellitus with sodium-glucose cotransporter 2 inhibitors.

Current opinion in nephrology and hypertension·2026
Same journal

Financial and policy challenges of delivering kidney replacement therapies in resource-limited settings.

Current opinion in nephrology and hypertension·2026
Same journal

The role of kir4.1/Kir5.1 in mediating the effect of angiotensin-II on Na-Cl-cotransporter.

Current opinion in nephrology and hypertension·2026
Same journal

Role of the calcium-sensing receptor in regulating calcium transport in the thick ascending limb.

Current opinion in nephrology and hypertension·2026
Same journal

Social determinants of chronic kidney disease: from association to clinical and population action.

Current opinion in nephrology and hypertension·2026
Same journal

Advancing science and care in CKD-MBD: the layered path to legacy.

Current opinion in nephrology and hypertension·2026
See all related articles

Diabetic nephropathy, a leading cause of kidney failure, requires new treatments. Recent research explores its pathology, genetics, and metabolic pathways, highlighting the need for improved prevention and intervention strategies.

Area of Science:

  • Nephrology
  • Endocrinology
  • Molecular Biology
  • Genetics

Background:

  • Diabetic nephropathy is the primary cause of end-stage renal disease, with incidence increasing despite therapeutic advances.
  • Structural changes in diabetic nephropathy can precede clinical manifestations, indicating a need for deeper pathological understanding.
  • Current understanding of functional consequences and genetic predispositions remains incomplete.

Purpose of the Study:

  • To review recent advancements in understanding the pathophysiology of diabetic nephropathy.
  • To identify emerging insights from molecular biology and genetics relevant to diabetic nephropathy.
  • To summarize research on potential new treatment approaches for diabetic nephropathy.

Main Methods:

Related Experiment Videos

  • Review of recent scientific literature on diabetic nephropathy.
  • Analysis of studies focusing on pathology, genetics, and metabolic pathways.
  • Synthesis of findings related to clinical manifestations and therapeutic interventions.

Main Results:

  • Advances in understanding diabetic nephropathy pathology, including structural changes preceding clinical signs.
  • Identification of candidate genes and genetic loci associated with diabetic nephropathy risk.
  • Recognition of perturbations in metabolic pathways and their link to the condition.
  • Emphasis on the critical role of glycemia and blood pressure control, with a need for novel modalities.

Conclusions:

  • Molecular biology and genetics offer new insights into diabetic nephropathy mechanisms.
  • Potential for early identification of at-risk patients and development of preventive strategies.
  • Strong recommendation for aggressive implementation of glycemic control and antihypertensive therapies, including renin-angiotensin system blockers.